Vulvar cancer (Squamous cell carcinoma): Advanced or recurrent/metastatic disease…Biomarker-directed systemic therapy for second-line treatment…Larotectinib or entrectinib for NTRK gene fusion-positive tumors...

We’re delighted to announce that a new drug, larotrectinib, has been approved for the treatment of certain sarcomas in England. ‘Sarcoma UK welcomes today’s approval of larotrectinib. Made available for use by the Cancer Drugs Fund and approved by NICE (National Institute for Health and Care Excellence) larotrectinib is a new type of ‘histologically-independent’ drug that targets tumours based on their genetic makeup. It works by targeting the specific NTKR genetic abnormality in tumours meaning patients are treated according to the genetics of their tumour rather than where it is in the body.